NCT07061977 - Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | Biotech Hunter

Enrollment

336

Participants

Timeline

Start Date

June 26, 2026

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions

Locally Advanced Cervical AdenocarcinomaLocally Advanced Cervical Adenosquamous CarcinomaLocally Advanced Cervical Squamous Cell CarcinomaStage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Stage IIIC1 Cervical Cancer FIGO 2018Stage IIIC2 Cervical Cancer FIGO 2018Stage IVA Cervical Cancer FIGO 2018

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

RADIATION

Brachytherapy

Undergo brachytherapy

DRUG

Carboplatin

Given IV

PROCEDURE

Chest Radiography

Undergo chest x-ray

DRUG

Cisplatin

Given IV

PROCEDURE

Computed Tomography

Undergo CT scan

RADIATION

External Beam Radiation Therapy

Undergo EBRT

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Paclitaxel

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET scan

Trial Locations (6)

43560

RECRUITING

ProMedica Flower Hospital, Sylvania

59804

RECRUITING

Community Medical Center, Missoula

65804

RECRUITING

Mercy Hospital Springfield, Springfield

68114

RECRUITING

Nebraska Methodist Hospital, Omaha

83814

RECRUITING

Kootenai Health - Coeur d'Alene, Coeur d'Alene

83854

RECRUITING

Kootenai Clinic Cancer Services - Post Falls, Post Falls

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH